Core Viewpoint - Organigram Global Inc. has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of the acquisition of Sanity Group GmbH, citing strong strategic rationale and institutional confidence in the transaction [1][3]. Acquisition Details - The acquisition involves a combination of cash and Organigram shares valued at C$3.00 per share for Sanity shareholders, representing a 71.4% premium over the last unaffected trading price [4]. - The total upfront consideration for the acquisition is €113.4 million, consisting of €80.0 million in cash and €33.4 million in Organigram shares, with potential contingent earn-out consideration of up to €113.8 million based on Sanity's financial performance post-closing [4]. Strategic Rationale - ISS highlighted that the acquisition will provide increased scale, geographic diversification, improved market presence, a stronger balance sheet, and enhanced cash flow generation for the combined company [3]. - The transaction is supported by a private placement financing from British American Tobacco, Organigram's largest shareholder, indicating strong institutional confidence [3]. Market Reaction - Following the announcement, Organigram's shares experienced a positive market reaction, outperforming both the S&P/TSX Composite Index and the S&P/TSX Composite Pharmaceuticals Index [10]. - ISS noted that the favorable market reaction suggests elevated risk if the transaction is not approved [10]. Board Support - The Board of Directors of Organigram unanimously recommends that shareholders vote in favor of the transaction, having consulted with financial and legal advisors and received a fairness opinion confirming the financial fairness of the deal [5][10]. Meeting Matters - In addition to the acquisition vote, shareholders will also vote on the election of ten director nominees, the appointment of PricewaterhouseCoopers LLP as auditor, and the re-approval of unallocated awards under the Omnibus Equity Incentive Plan, with the Board recommending support for all these matters [6].

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, the company harvested over 28,000 kilograms of flower, representing a 43% year-over-year increase, driven by improving yields and ongoing refinements to nutrient programs [10] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][9] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by the success of vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while also looking at future international expansion opportunities [29][30] - The company aims to balance risk and growth opportunities in international markets while maintaining a strong focus on consumer needs and innovation [30] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management noted that Q1 results reflected strong year-over-year revenue and adjusted EBITDA growth, despite seasonal resets and operational pressures [16] - The company remains confident in its ability to deliver against full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals and expanding margins [24] - Management expressed optimism about international sales growth in fiscal 2026, despite a temporary decline in international volumes due to product specifications [12][13] Other Important Information - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for early screening of seedlings and reducing crop loss [11] - The company completed commissioning of its beverage line and began in-house production to support portfolio expansion [12] - The company is preparing for EU GMP certification and is working closely with regulators to address feedback received [13][48] Q&A Session Summary Question: Near-term opportunities and long-term initiatives - Management emphasized the importance of operational execution and cost management as short-term priorities, while focusing on international expansion as a long-term goal [29][30] Question: Insight on international volumes and flower issues - Management acknowledged stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact of the flower issues was approximately CAD 3.5 million on international revenue [36] Question: Recovery in the Canadian market - Management confirmed that distribution levels in BC have returned to normal and expressed confidence in recovering market share despite increased competition [42] Question: EU GMP certification timeline - Management stated they are working closely with regulators to address questions and are aiming for the fastest resolution possible, but could not provide a specific timeline [48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations and market conditions [52] Question: U.S. market strategy and regulatory environment - Management noted that the U.S. market is currently a small part of their business and emphasized a cautious approach to investments due to regulatory uncertainties [55][56] Question: Increased competition in pre-rolls - Management acknowledged competitive pressures across all categories, particularly in pre-rolls and vapes, and highlighted upcoming product innovations to address these challenges [60]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, the integration of Motif, and higher international sales [16] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher yields and lower cultivation costs [16][17] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period [19] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period [19] Business Line Data and Key Metrics Changes - International sales for Q1 were CAD 5 million, up 51% over Q1 last year, despite a sequential decline due to higher-than-expected out-of-spec flower [16][12] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [7][6] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][7] Market Data and Key Metrics Changes - In Canada, the company held the number one market share position with 11.3% total share in Q1 and 11.7% over the past 12 months [5] - Market share in Quebec improved to the number three position with 9.9% for the quarter, driven by successful vape launches [6] - The company outperformed in several provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [7] Company Strategy and Development Direction - The company aims to focus on operational execution, cost base improvement, and margin enhancement in the short term, while pursuing international expansion in the long term [28] - The company is optimistic about the long-term growth of the cannabis industry and its ability to compete and lead as growth continues [5] - New product innovations, including SHRED Soda and SHRED Shots, are expected to enhance market competitiveness [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC labor strike and increased competition in vapes and pre-rolls but expressed confidence in recovering sales and maintaining adjusted gross margins [15][19] - The company is addressing temporary issues with international flower specifications and expects to return to normal operating parameters [12][34] - Management remains confident in delivering against full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals and expanding margins [23] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase [10] - The company is in the final phases of ERP implementation, with expectations for associated costs to roll off after the second quarter [18] - The company is preparing for EU GMP certification and is working closely with regulators to address feedback received [46] Q&A Session Summary Question: Near-term opportunities and long-term initiatives - Management emphasized the focus on operational execution and cost base improvement in the short term, while balancing future growth opportunities in international markets [27][28] Question: Insights on international volumes and flower issues - Management noted that stringent international flower requirements led to temporary issues, with an estimated CAD 3.5 million impact on international revenue [34][35] Question: Recovery in the Canadian market - Management confirmed that sales in BC have returned to traditional distribution levels and expressed confidence in addressing increased competition with new product launches [41][42] Question: EU GMP certification timeline - Management stated that they are working closely with regulators to resolve questions and are aiming for the fastest timeline possible, though no specific date can be provided [46] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations and market conditions [50][51] Question: U.S. market strategy and regulatory environment - Management highlighted that the U.S. market is currently a minor part of the business and emphasized a cautious approach to investment until regulatory clarity is achieved [54][55]

Core Insights - Organigram Global Inc. reported strong year-over-year growth in Q1 Fiscal 2026, driven by Canadian market leadership and increasing international sales, alongside improved gross margins [1][2] Financial Performance - Net revenue increased by 49% to $63.5 million from $42.7 million in Q1 Fiscal 2025, primarily due to contributions from the Motif Labs acquisition and higher international sales [1][2] - Adjusted gross margin rose to $23.9 million, or 38% of net revenue, compared to $14.3 million, or 33%, in Q1 Fiscal 2025, attributed to operational efficiencies and higher flower yields [1][2] - Adjusted EBITDA reached $5.3 million, a 273% increase year-over-year, driven by higher recreational and international revenue [1][2] Operational Highlights - The company harvested 28,645 kilograms, a 43% increase compared to Q1 Fiscal 2025, achieved through nutrient and environmental enhancements [1] - Organigram launched its Collective Project and Fetch brands into Illinois and Wisconsin, expanding its U.S. retail footprint to 11 states [1] - The company achieved a proprietary genetic screening breakthrough for powdery mildew resistance, significantly reducing identification time [1] Market Position - Organigram holds the 1 market share in Canada for vapes, milled flower, and concentrates, and ranks 2 in pre-rolls and 3 in edibles and dried flower [1] - International sales reached $5.0 million, a 51% increase year-over-year, with expectations for continued growth [1][2] Balance Sheet and Liquidity - As of December 31, 2025, the company had total cash of $63.0 million, with total assets amounting to $530.7 million [2] - Total liabilities decreased by 24% to $161.2 million, while shareholders' equity increased by 6% to $369.5 million [2]